20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock

On July 23, 2026 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, reported that it has entered into a standstill agreement (the "Agreement") with Streeterville Capital, LLC ("Streeterville") relating to the Company’s outstanding Series E Convertible Preferred Stock (the "Series E Preferred Stock"). The Agreement became effective on July 16, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the Agreement, during the 120-day period beginning on the date of the Agreement, Streeterville has agreed not to convert any shares of Series E Preferred Stock into shares of the Company’s common stock unless, on a given trading day, the common stock trades at a price at least 10% above the "Minimum Price" (as defined under Nasdaq Rule 5635) (the "Standstill") provided that the Standstill shall terminate immediately upon the occurrence of any breach of the Agreement or any Event of Default (as defined in the Certificate of Designation for the Series E Preferred Stock). The Agreement temporarily limits potential dilution from conversions of the Series E Preferred Stock while preserving the existing rights and obligations of both parties under the related transaction documents.

Upon expiration or termination of the Standstill, Streeterville may resume converting shares of the Series E Preferred Stock in accordance with the terms of the applicable transaction documents. Except as expressly provided in the Agreement, the Series E Preferred Stock and all related transaction documents remain in full force and effect.

Additional information regarding the Agreement will be included in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission.

(Press release, 20/20 GeneSystems, JUL 23, 2026, View Source [SID1234669411])